Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

IMMUNOTHERAPY

Tumors evading CARs—the chase is on

Nature Medicine volume 24, pages 1492–1493 (2018)Cite this article

Subjects

Acquired resistance to CD19-targeted CAR T cell therapy can occur through mutations in the CD19 gene or after insertion of a chimeric antigen receptor (CAR) into leukemia cells, resulting in the adjacent receptor being masked by the CAR.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: CD19 antigen escape from CAR T cell therapy.

References

  1. Majzner, R. G. & Mackall, C. L. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-18-0442 (2018).

    Article  Google Scholar 

  2. Orlando, E. J. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0146-z (2018).

  3. Ruella, M. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0201-9 (2018).

  4. Sotillo, E. et al. Cancer Discov. 5, 1282–1295 (2015).

  5. Sommermeyer, D. et al. Leukemia 31, 2191–2199 (2017).

    Article  CAS  Google Scholar 

  6. Bagashev, A. et al. Mol. Cell. Biol. https://doi.org/10.1128/MCB.00383-18 (2018).

  7. Fischer, J. et al. J. Immunother. 40, 187–195 (2017).

    Article  CAS  Google Scholar 

  8. Ali, S. A. et al. Blood 128, 1688–1700 (2016).

    Article  CAS  Google Scholar 

  9. Cho, J. H., Collins, J. J. & Wong, W. W. Cell 173, 1426–1438.e11 (2018).

    Article  CAS  Google Scholar 

  10. Jackson, H. J., Rafiq, S. & Brentjens, R. J. Nat. Rev. Clin. Oncol. 13, 370–383 (2016).

    Article  CAS  Google Scholar 

  11. Avanzi, M. P. et al. Cell Reports 23, 2130–2141 (2018).

    Article  CAS  Google Scholar 

  12. Rafiq, S. et al. Nat. Biotechnol. 36, 847–856 (2018).

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Sarwish Rafiq & Renier J. Brentjens

  2. Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Sarwish Rafiq & Renier J. Brentjens

  3. Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA

    Renier J. Brentjens

Authors
  1. Sarwish Rafiq
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renier J. Brentjens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renier J. Brentjens.

Ethics declarations

Competing interests

R.J.B. is a cofounder of and receives royalties from Juno Therapeutics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rafiq, S., Brentjens, R.J. Tumors evading CARs—the chase is on. Nat Med 24, 1492–1493 (2018). https://doi.org/10.1038/s41591-018-0212-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-018-0212-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing